These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16918309)

  • 1. Ribonucleotide reductase inhibitors and future drug design.
    Shao J; Zhou B; Chu B; Yen Y
    Curr Cancer Drug Targets; 2006 Aug; 6(5):409-31. PubMed ID: 16918309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting ribonucleotide reductase for cancer therapy.
    Shao J; Liu X; Zhu L; Yen Y
    Expert Opin Ther Targets; 2013 Dec; 17(12):1423-37. PubMed ID: 24083455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase.
    Shao J; Zhou B; Zhu L; Qiu W; Yuan YC; Xi B; Yen Y
    Cancer Res; 2004 Jan; 64(1):1-6. PubMed ID: 14729598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
    Mannargudi MB; Deb S
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1499-1529. PubMed ID: 28624910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
    Li J; Zheng LM; King I; Doyle TW; Chen SH
    Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
    Tsimberidou AM; Alvarado Y; Giles FJ
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):437-48. PubMed ID: 12647987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy.
    Cerqueira NM; Pereira S; Fernandes PA; Ramos MJ
    Curr Med Chem; 2005; 12(11):1283-94. PubMed ID: 15974997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-guided design of anti-cancer ribonucleotide reductase inhibitors.
    Misko TA; Liu YT; Harris ME; Oleinick NL; Pink J; Lee HY; Dealwis CG
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):438-450. PubMed ID: 30734609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of 2,2'-bipyridyl-6-carbothioamide: a ribonucleotide reductase inhibitor.
    Nocentini G; Barzi A
    Gen Pharmacol; 1997 Nov; 29(5):701-6. PubMed ID: 9347313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
    Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
    Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and virtual screening towards synthesis of novel substituted thiosemicarbozones as ribonuleotide reductase (RNR) inhibitors with improved cellular trafficking and anticancer activity.
    Gokhale N; Jain S; Yadav M
    Curr Top Med Chem; 2015; 15(1):37-42. PubMed ID: 25579572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase.
    Zhu L; Zhou B; Chen X; Jiang H; Shao J; Yen Y
    Biochem Pharmacol; 2009 Nov; 78(9):1178-85. PubMed ID: 19576866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
    Nandy P; Lien EJ; Avramis VI
    Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Iminodiacetate-Thiosemicarbazone Hybrids and Their Copper(II) Complexes Are Potential Ribonucleotide Reductase R2 Inhibitors with High Antiproliferative Activity.
    Zaltariov MF; Hammerstad M; Arabshahi HJ; Jovanović K; Richter KW; Cazacu M; Shova S; Balan M; Andersen NH; Radulović S; Reynisson J; Andersson KK; Arion VB
    Inorg Chem; 2017 Mar; 56(6):3532-3549. PubMed ID: 28252952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity.
    Finch RA; Liu MC; Cory AH; Cory JG; Sartorelli AC
    Adv Enzyme Regul; 1999; 39():3-12. PubMed ID: 10470363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits.
    Xue L; Zhou B; Liu X; Qiu W; Jin Z; Yen Y
    Cancer Res; 2003 Mar; 63(5):980-6. PubMed ID: 12615712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.
    Huff SE; Winter JM; Dealwis CG
    Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay.
    Shao J; Zhou B; Zhu L; Bilio AJ; Su L; Yuan YC; Ren S; Lien EJ; Shih J; Yen Y
    Biochem Pharmacol; 2005 Feb; 69(4):627-34. PubMed ID: 15670581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents.
    Cerqueira NM; Fernandes PA; Ramos MJ
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):11-29. PubMed ID: 18221051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
    Cappellacci L; Franchetti P; Vita P; Petrelli R; Lavecchia A; Jayaram HN; Saiko P; Graser G; Szekeres T; Grifantini M
    J Med Chem; 2008 Jul; 51(14):4260-9. PubMed ID: 18588281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.